Open-Angle Glaucoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Aerpio, Annexon, GrayBug, Ocular Therapeutix, Ocularis Pharma, PolyActiva, Qlaris Bio, SALVAT

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Open-Angle Glaucoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Open-Angle Glaucoma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Open-Angle Glaucoma Therapeutics Market.

The report provides a detailed description of the Open-Angle Glaucoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Open-Angle Glaucoma Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Open-Angle Glaucoma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Open-Angle Glaucoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Open-Angle Glaucoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Open-Angle Glaucoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Open-Angle Glaucoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Open-Angle Glaucoma Therapeutics Domain @
https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Open-Angle Glaucoma Therapeutics Analysis
There are approx. 20+ key companies developing therapies for Open-Angle Glaucoma. Currently, Ocular Therapeutix is leading the therapeutics market with its Open-Angle Glaucoma drug candidates in the most advanced stage of clinical development.

Open-Angle Glaucoma Companies in the Therapeutics Market Include:
• AbbVie
• Aerpio Pharmaceuticals
• Annexon
• GrayBug
• Ocular Therapeutix
• Ocularis Pharma
• PolyActiva
• Qlaris Bio
• Quark Pharmaceuticals
• SALVAT
• Skye Bioscience
And Many Others

Emerging and Marketed Open-Angle Glaucoma Therapies Covered in the Report Include:
• QLS-101: Qlaris Bio
• Razuprotafib: Aerpio Pharmaceuticals
And Many More

Get an in-depth Assessment of the Emerging Therapies and Open-Angle Glaucoma Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Open-Angle Glaucoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Open-Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Open-Angle Glaucoma Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Open-Angle Glaucoma Current Treatment Patterns
4. Open-Angle Glaucoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Open-Angle Glaucoma Late-Stage Products (Phase-III)
7. Open-Angle Glaucoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Open-Angle Glaucoma Discontinued Products
13. Open-Angle Glaucoma Product Profiles
14. Open-Angle Glaucoma Companies
15. Open-Angle Glaucoma Drugs
16. Dormant and Discontinued Products
17. Open-Angle Glaucoma Unmet Needs
18. Open-Angle Glaucoma Future Perspectives
19. Open-Angle Glaucoma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.